Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zelos Therapeutics and Nektar have initiated a phase I clinical trial of an inhaled powder formulation of Zelos' proprietary parathyroid hormone Ostabolin-C.
Subscribe to our email newsletter
Nektar and Zelos entered into a collaboration to develop an inhaleable powder form of Ostabolin-C in January 2005.
Inhaled Ostabolin-C uses Nektar’s small, pocket-sized inhaler to deliver a peptide and it is designed to provide a portable and easy-to-use solution for patients.
“Ostabolin-C is a powerful new bone formation agent that we believe will emerge as a best-in-class PTH for the treatment of osteoporosis. A key to expanding the market for bone formation therapies will be the development of convenient non-injectable delivery alternatives that can improve both patient compliance and thus, treatment outcomes in osteoporosis,” commented Brian MacDonald, CEO of Zelos.
“This product has the potential to address the need for a more convenient, patient-friendly and much-needed therapy option for osteoporosis patients,” said David Johnston, senior vice president of R&D at Nektar.
The phase I trial will enroll up to 56 healthy postmenopausal women. The primary study endpoints are the safety and tolerability of Ostabolin-C. The study will also assess effect of inhaled Ostabolin-C on serum markers of bone formation and resorption.